Medigene's drug Veregen® launched in Norway and Sweden
Medigene AG /
Medigene's drug Veregen® launched in Norway and Sweden
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Market approval in Greece obtained
Martinsried/Munich, 18 December 2013. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces that the company's marketing partner Azanta A/S will start
the launch of the drug Veregen(®) for the treatment of genital warts in Norway
this week. Market launch in Sweden is scheduled early in 2014. Pursuant to the
license agreement, Medigene receives proceeds from the manufacture and supply of
the ointment, as well as a double-digit percentage of the Veregen(®) sales
revenue as royalties.
Medigene further announces that Veregen(®) has obtained market approval in
Greece. All 17 European countries participating in the current mutual
recognition procedure have granted market approvals for Veregen(®). Submission
of marketing authorization applications in nine additional European countries
within the mutual recognition procedure is planned for 2014.
Veregen(®) is already available in the USA, Germany, Austria, Switzerland,
Spain, Serbia, the Netherlands, and Taiwan. Market approvals for Veregen(®) have
been granted in a number of other countries. Further market launches and
approvals of Veregen(®) are expected in 2014. Several marketing agreements have
been concluded in Europe, Asia, and America. Medigene is planning to continue
this global licensing strategy to further tap the product's market potential.
About Veregen(®): Veregen(®), a topical treatment for external genital or
perianal warts, contains a concentrate of catechins with a complex defined
composition extracted from green tea leaves. In its current treatment guidelines
for sexually transmitted diseases, the US Center for Disease Control and
Prevention recommends Sinecatechins 15% ointment (Veregen(®)) as a possible
option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment
(Veregen(®)) has been included in the current European guideline on the
treatment of genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
About Azanta: Azanta A/S is a privately owned specialty pharma company primarily
operating within oncology, women's and men's health, and addiction medicine. The
vision of Azanta A/S is to become an international market leader for specialty
pharma products and innovative pharmaceutical products. Azanta A/S currently
markets nine specialty pharma products, including Nimoral, a hypoxic
radiosensitizer for the treatment of head and neck cancer patients undergoing
primary radiotherapy. In addition, Azanta A/S has a portfolio of low-risk
development projects for commercialization in the near term. For further
information, please visit www.azanta.com.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from a
marketed product, Veregen(®), which is distributed by partner companies. It has
two drug candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®); and is
developing an innovative vaccine technology. Further information at
www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®), Veregen(®), EndoTAG(®) and RhuDex(®) are registered trademarks of
Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press release distribution list, please go to:
www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1750526/589911.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1750526]
